The objective of this Clinical Practice Guideline (CPG) is to provide evidence-based practice recommendations for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The CPG discusses the importance of developing and following a COPD Action Plan as well as items related to integrated care management of COPD such as behavioral health implications. In addition, the CPG outlines the organizations that WellCare aligns with regarding COPD and relevant Measureable Health Outcomes.
The Global Initiative for Chronic Obstructive Lung Disease published a 2016 update to the report, A Global Strategy for Diagnosis, Management, and Prevention of COPD. Components of the report include assessing and monitoring disease, reducing risk factors, managing stable COPD, and managing exacerbations. The full report can be accessed at http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/.
Evidence Based Practice

MEASUREMENT OF COMPLIANCE
WellCare is committed to adhering to the measures and standards published by the Centers for Medicare and Medicaid Services (CMS) and the National Committee for Quality Assurance (NCQA). Please reference WellCare's Clinical Policy Guiding Document titled Measures of Compliance.
NOTE: To access Clinical Policy Guiding Documents visit www.wellcare.com -select the Provider tab, then "Tools" and "Clinical Guidelines".
Care Management
The goals for Care Management is to support the member's ability to self-manage their disease, minimize risks of chronic obstructive pulmonary disease, and remove barriers preventing the member from achieving those goals. Primary symptoms to educate member on include: 3 Member follows COPD Action Plan and calls physician right away to report:
Member should seek immediate medical care for:  More breathless than usual  Severe shortness of breath even at rest  less energy for my daily activities  Not able to do any activity because of breathing  Increased or thicker phlegm/mucus  Not able to sleep because of breathing  Swelling of ankles more than usual  Fever or shaking chills  More coughing than usual  Feeling confused or very drowsy  Feels like a "chest cold"
 
CASE MANAGEMENT GOALS
Case Goals should target specific care gaps and/or adherence issues, and measure the Member's progress towards self-management and adherence which will lead to the targeted health outcomes above. Examples:  Member's prescription refills demonstrate at least an 80% adherence rate (verified by claims or Member/Provider narrative for [bronchodilator, inhaled glucocorticosteroids, systemic corticosteroid, other] over last 30 days).  Member describes prescribed and safe use of oxygen at home and / or while away from home over the last 30 days, meeting physician prescribed oxygen regime and / or matching Member's COPD Action Plan.  Member describes the use of infection prevention measures (such as handwashing) over the last 30 days and has received annual flu vaccine and pneumococcal vaccine if appropriate for age and risk factors.  Specific for Members requiring hospitalization: The Member participates in provider follow-up visit within 7 days of hospital discharge.
Member is able to describe steps taken to minimize exposure to and/or avoid COPD triggers and irritants as measured by Member's description of known triggers and avoidance strategies (pre-and post-case management intervention).
CASE MANAGEMENT OBJECTIVES
Case Management Objectives should focus on improving the Member's self-management skills including:  Implementing a COPD Action Plan  Using oxygen safely  Using airway clearing and/or pursed lip breathing techniques  Tobacco cessation  Avoiding fumes, dust, second-hand smoke and other lung irritants  Staying as active as possible  Taking medications as prescribed including control medications and rescue inhalers / treatments  Attending all appointments as scheduled  Frequent handwashing to prevent infection
The care team should also conduct risk screening and treat co-morbid anxiety and depression, if applicable. Additional Care Management training items are located in the Addendum of this CPG.
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The following are important behavioral health concerns when managing those with COPD: 4  Intense anxiety can mimic a COPD exacerbation, and giving bronchodilators will worsen the anxiety.  Physical symptoms such as loss of appetite and weight, trouble sleeping due to agitation, low energy, and poor concentration can be very responsive to antidepressant medications.  Substance use disorders may be co-occurring as smoking (nicotine dependence) frequently is accompanied by alcohol use/dependence.  Excessive worry can lead to demoralization, which is a persistent failure to cope with a chronic stressor. In one ER study, those treated with an inhaler for asthma improved their rating of comfort, even when their oxygen saturation levels did not increase. 
MEMBER EDUCATIONAL RESOURCES
Related WellCare Guidelines
In addition to the information contained in this document, please reference the following CPGs: Asthma (HS-1001) and
Smoking Cessation (HS-1035). The age-specific Preventive Health CPGs (Adolescent: HS-1051, Adult: HS-1018, and
Older Adult: HS-1063), for additional measures related to healthy behaviors (like smoking cessation), and general medication prescribing, reconciliation, and adherence monitoring.
NOTE: Clinical Policies can be accessed by going to www.wellcare.com -select the Provider tab, then "Tools" and "Clinical Guidelines".
deficiencies in the information contained herein or for any inaccuracies or recommendations made by independent third parties from whom any of the information contained herein was obtained.
Links are current at time of approval by the Medical Policy Committee (MPC) and are subject to change. Lines of business are also subject to change without notice and are noted on www.wellcare.com. Guidelines are also available on the site by selecting the Provider tab, then "Tools" and "Clinical Guidelines". 
Addendum
Symptoms of COPD 5
Cough can be expected with COPD. Cough is a natural reaction of the airways to try and remove mucus or it can be a reaction to protect the airways from inhaled irritants.
Dyspnea, or shortness of breath, is a common symptom of COPD. Breathlessness is a feeling occurring when the lung changes from working in the way it was normally designed to work, to working differently. If the lung senses that it takes more work or effort to move air in and out of the lungs, a feeling of breathlessness will be experienced.
It is normal for the airways to produce several ounces of sputum a day. This mucus is needed to keep the breathing passages moist. When the lungs are bothered by irritants, they try to protect themselves by producing additional mucus to trap any inhaled particles from entering the lungs.
Like breathlessness, tiredness is an uncomfortable feeling. It is a common symptom in people with COPD. Tiredness is a feeling of loss of energy or stamina. Generally, breathlessness and tiredness go hand in hand and they are, for some people, difficult to tell apart.
Stages of COPD 5
 Stage I: Mild. Individual may not be aware that his or her lung function is abnormal. Mild airflow limitation (FEV1/FVC < 70%; FEV1 ≥ 80% predicted) and sometimes, but not always, chronic cough and sputum production.  Stage II: Moderate. Individuals typically seek medical attention because of chronic respiratory symptoms or an exacerbation of their disease. Worsening airflow limitation (FEV1/FVC < 70%; 50% ≤ FEV1 < 80% predicted) with shortness of breath typically developing on exertion.  Stage III: Severe. Airflow limitation, greater shortness of breath, reduced exercise capacity, and repeated exacerbations which have an impact on patient's quality of life. Further worsening of airflow limitation (FEV1/FVC < 70%; 30% ≤ FEV1 < 50 % predicted), greater shortness of breath, and reduced exercise capacity is expected.  Stage IV: End Stage. Quality of life is very appreciably impaired and exacerbations may be life-threatening.
Severe airflow limitation (FEV1/FVC < 70%; FEV1 < 30% predicted) or FEV1 < 50% predicted plus chronic respiratory failure. Patients may have Very Severe (Stage IV) COPD even if the FEV1 > 30% predicted, whenever this complication is present.
Spirometry is a Key Diagnostic Test 5
Spirometry is the gold standard for diagnosing COPD because it is the most standardized and reproducible measurement of airflow limitation. It measures the amount and speed at which a person can exhale after a deep
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) HS-1007
breath. Symptomatic and asymptomatic patients suspected of having COPD should have spirometry performed to determine airway limitation and disease severity. Only one in three patients newly diagnosed with COPD receives a spirometry-based screening.
Key Indicators for Considering a COPD Diagnosis
Consider COPD and perform spirometry if any of the following indicators are present in an individual over age 40:
 Dyspnea that is progressive, worse with exercise, persistent (present every day) and described by the patient as an "increased effort to breathe, "heaviness", "gasping", etc. 
Differential Diagnosis of COPD 5
Asthma: Onset early in life; symptoms vary from day to day; symptoms at night/early morning; allergy, rhinitis and/or eczema also present; family history of asthma; largely reversible airflow limitation.
Bronchiectasis: Large volumes of purulent sputum; commonly associated with bacterial infection; coarse crackles/clubbing on auscultation; chest X-ray/CT shows bronchial dilation, bronchial wall thickening.
Congestive Heart Failure: Fine basilar crackles on auscultation; chest X-ray shows dilated heart, pulmonary edema; pulmonary function tests indicate volume restriction, not airflow limitation.
Diffuse Panbronchiolitis: Most patients are male and nonsmokers; almost all have chronic sinusitis; chest X-ray and HRCT show diffuse small centrilobular nodular opacities and hyperinflation.
Obliterative Bronchiolitis: Onset in younger age; non-smokers; may have history of rheumatoid arthritis or fume exposure; CT on expiration shows hypodense areas.
Tuberculosis: Onset all ages; chest X-ray shows lung infiltration or nodular lesions; microbiological confirmation; high local prevalence of tuberculosis.
